Friday, November 20, 2026

ADEL Withdraws Kosdaq Listing Bid After Failing to Clear Demand Forecast Hurdle

Input
2026-11-20 16:46:07
Updated
2026-11-20 16:46:07

[Financial News] ADEL, a biotech company developing treatments for degenerative brain diseases, has halted its push to list on Kosdaq.
The decision is believed to reflect the company's view that it would be difficult to proceed with the offering, after it received a weaker-than-expected assessment in demand forecasting among institutional investors and amid a recent downturn in the stock market.
ADEL disclosed that on the 20th it filed a withdrawal report with the Financial Services Commission, canceling the remaining schedule for its initial public offering (IPO). It had been proceeding with the offering with a listing targeted for early next month, but decided to abandon its listing plan after the demand forecast.
The company said of its reason for withdrawing, "Although we conducted demand forecasting for an offering of common shares, after consulting with the joint lead managers and taking into account overall conditions, including the difficulty of having the company's value appropriately assessed in the current environment, we are canceling the remaining schedule." It added that there were no investor-protection concerns, as it withdrew before the date for subscriptions to acquire or purchase securities.
ADEL had initially planned to offer a total of 2.17 million shares, targeting a Kosdaq listing on the 2nd of next month. The indicative price range was 18,000 to 25,000 won, with the planned offering expected to raise about 39.1 billion to 54.3 billion won.
Demand forecasting for institutional investors ran from the 12th to the 18th. The market believes the listing withdrawal followed after institutional investors' assessments during the demand forecast fell short even of the lower end of the indicative price range, 18,000 won.
The company had initially maintained that the recent market conditions and the timing of its listing push had coincided by chance. ADEL CEO Yoon Seung-yong said at a press conference on the 18th, "We are listing now after proceeding with the listing process in stages as planned," and added, "The unfavorable market conditions just happened to coincide with this."
However, the company appears to have concluded that it would be difficult to proceed with the offering as originally planned after reviewing the actual demand-forecast results. With investor sentiment in the Kosdaq market recently weakening, institutional investors' valuation expectations also became a factor in the company's listing push.
The withdrawal of the listing has also inevitably disrupted its research and development (R&D) plans, which were to be funded with the IPO proceeds. ADEL had planned to use the funds raised through the IPO for preclinical and clinical development of follow-on pipeline candidates, further development of its next-generation brain-delivery platform, and the identification of new pipeline candidates.
With fundraising through the listing now off the table, the company must consider other ways to secure funding for those projects. In particular, as clinical-stage drug development advances, the R&D cost burden grows, so the company is likely to have to draw up a new fundraising plan.
ADEL was established in 2016 as a spin-off from the University of Ulsan College of Medicine at Asan Medical Center in Seoul. It is developing treatments for degenerative brain diseases, including Alzheimer's disease, as its main pipeline. With the withdrawal, its plan to raise substantial funds through a Kosdaq listing this year has, for now, fallen through.

[email protected] Kang Jung-mo Reporter